{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:25:48Z","timestamp":1781133948437,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/nrendo.2013.113","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T06:35:14Z","timestamp":1370932514000},"page":"467-478","source":"Crossref","is-referenced-by-count":48,"title":["New pharmacological approaches for obesity management"],"prefix":"10.1038","volume":"9","author":[{"given":"Christian F.","family":"Rueda-Clausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj S.","family":"Padwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya M.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"key":"BFnrendo2013113_CR1","unstructured":"WHO. Obesity and overweightfact sheet N.\u00b0311. WHO Media Centre \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrendo2013113_CR2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/sj.ijo.0802366","volume":"27","author":"J Kaukua","year":"2003","unstructured":"Kaukua, J., Pekkarinen, T., Sane, T. & Mustajoki, P. Health-related quality of life in obese outpatients losing weight with very-low-energy diet and behaviour modification: a 2-y follow-up study. Int. J. Obes. Relat. Metab. Disord. 27, 1072\u20131080 (2003).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"BFnrendo2013113_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhealeco.2011.10.003","volume":"31","author":"J Cawley","year":"2012","unstructured":"Cawley, J. & Meyerhoefer, C. The medical care costs of obesity: an instrumental variables approach. J. Health Econ. 31, 219\u2013230 (2012).","journal-title":"J. Health Econ."},{"key":"BFnrendo2013113_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jada.2007.07.017","volume":"107","author":"MJ Franz","year":"2007","unstructured":"Franz, M. J.  et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J. Am. Diet Assoc. 107, 1755\u20131767 (2007).","journal-title":"J. Am. Diet Assoc."},{"key":"BFnrendo2013113_CR5","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1038\/nutd.2011.21","volume":"2","author":"B Perry","year":"2012","unstructured":"Perry, B. & Wang, Y. Appetite regulation and weight control: the role of gut hormones. Nutr. Diabetes 2, e26 (2012).","journal-title":"Nutr. Diabetes"},{"key":"BFnrendo2013113_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","volume":"365","author":"P Sumithran","year":"2011","unstructured":"Sumithran, P.  et al. Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 365, 1597\u20131604 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013113_CR7","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1152\/ajpregu.00053.2009","volume":"298","author":"R Goldsmith","year":"2010","unstructured":"Goldsmith, R.  et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R79\u2013R88 (2010).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"BFnrendo2013113_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/35007534","volume":"404","author":"MW Schwartz","year":"2000","unstructured":"Schwartz, M. W., Woods, S. C., Porte, D. Jr, Seeley, R. J. & Baskin, D. G. Central nervous system control of food intake. Nature 404, 661\u2013671 (2000).","journal-title":"Nature"},{"key":"BFnrendo2013113_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm0612-843","volume":"18","author":"E Dolgin","year":"2012","unstructured":"Dolgin, E. A history of drugs on the weight list. Nat. Med. 18, 843 (2012).","journal-title":"Nat. Med."},{"key":"BFnrendo2013113_CR10","first-page":"377","volume":"5","author":"SP Vickers","year":"2004","unstructured":"Vickers, S. P. & Dourish, C. T. 5-hydroxytryptamine receptor ligands and the treatment of obesity. Curr. Opin. Investig. Drugs 5, 377\u2013388 (2004).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrendo2013113_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1586\/erc.09.123","volume":"7","author":"HE Bays","year":"2009","unstructured":"Bays, H. E. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert Rev. Cardiovasc. Ther. 7, 1429\u20131445 (2009).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"BFnrendo2013113_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly, H. M.  et al. Valvular heart disease associated with fenfluramine\u2013phentermine. N. Engl. J. Med. 337, 581\u2013588 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013113_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature05026","volume":"443","author":"GJ Morton","year":"2006","unstructured":"Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S. & Schwartz, M. W. Central nervous system control of food intake and body weight. Nature 443, 289\u2013295 (2006).","journal-title":"Nature"},{"key":"BFnrendo2013113_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","volume":"6","author":"L Zhou","year":"2007","unstructured":"Zhou, L.  et al. 5-hydroxytryptamine 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signalling pathways. Cell Metab. 6, 398\u2013405 (2007).","journal-title":"Cell Metab."},{"key":"BFnrendo2013113_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith, S. R.  et al. Multicentre, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 363, 245\u2013256 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2013113_CR16","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler, M. C.  et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96, 3067\u20133077 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013113_CR17","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PM O'Neil","year":"2012","unstructured":"O'Neil, P. M.  et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 20, 1426\u20131436 (2012).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2013113_CR18","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1152\/japplphysiol.00313.2003","volume":"95","author":"MM Wilson","year":"2003","unstructured":"Wilson, M. M. & Morley, J. E. Invited review: Aging and energy balance. J. Appl. Physiol. 95, 1728\u20131736 (2003).","journal-title":"J. Appl. Physiol."},{"key":"BFnrendo2013113_CR19","unstructured":"Arena Pharmaceuticals. FDA Briefing Document NDA 22529 Lorqess (lorcaserin hydrochloride) tablets, 10 mg \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrendo2013113_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","volume":"26","author":"CK Haddock","year":"2002","unstructured":"Haddock, C. K., Poston, W. S., Dill, P. L., Foreyt, J. P. & Ericsson, M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord. 26, 262\u2013273 (2002).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"BFnrendo2013113_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"JF Munro","year":"1968","unstructured":"Munro, J. F., MacCuish, A. C., Wilson, E. M. & Duncan, L. J. Comparison of continuous and intermittent anorectic therapy in obesity. Br. Med. J. 1, 352\u2013354 (1968).","journal-title":"Br. Med. J."},{"key":"BFnrendo2013113_CR22","unstructured":"Phentermine in AHFS Drug Information (American Society of Health-System Pharmacists, 2005)."},{"key":"BFnrendo2013113_CR23","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2165\/00003495-199243060-00003","volume":"43","author":"T Silverstone","year":"1992","unstructured":"Silverstone, T. Appetite suppressants. A review. Drugs 43, 820\u2013836 (1992).","journal-title":"Drugs"},{"key":"BFnrendo2013113_CR24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3349\/ymj.2006.47.5.614","volume":"47","author":"KK Kim","year":"2006","unstructured":"Kim, K. K., Cho, H. J., Kang, H. C., Youn, B. B. & Lee, K. R. Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. Yonsei Med. J. 47, 614\u2013625 (2006).","journal-title":"Yonsei Med. J."},{"key":"BFnrendo2013113_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","volume":"144","author":"M Weintraub","year":"1984","unstructured":"Weintraub, M., Hasday, J. D., Mushlin, A. I. & Lockwood, D. H. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch. Intern. Med. 144, 1143\u20131148 (1984).","journal-title":"Arch. Intern. Med."},{"key":"BFnrendo2013113_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","volume":"95","author":"A Verrotti","year":"2011","unstructured":"Verrotti, A.  et al. Topiramate-induced weight loss: a review. Epilepsy Res. 95, 189\u2013199 (2011).","journal-title":"Epilepsy Res."},{"key":"BFnrendo2013113_CR27","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","volume":"12","author":"CK Kramer","year":"2011","unstructured":"Kramer, C. K.  et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes. Rev. 12, e338\u2013e347 (2011).","journal-title":"Obes. Rev."},{"key":"BFnrendo2013113_CR28","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding, J., Van Gaal, L., Rissanen, A., Vercruysse, F. & Fitchet, M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int. J. Obes. Relat. Metab. Disord. 28, 1399\u20131410 (2004).","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"BFnrendo2013113_CR29","unstructured":"Roberts, M. Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting for phentermine\/topiramate (Qnexa) \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrendo2013113_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison, D. B.  et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20, 330\u2013342 (2012).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2013113_CR31","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde, K. M.  et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377, 1341\u20131352 (2011).","journal-title":"Lancet"},{"key":"BFnrendo2013113_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey, W. T.  et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 95, 297\u2013308 (2012).","journal-title":"Am. J. Clin. Nutr."},{"key":"BFnrendo2013113_CR33","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.amjcard.2012.12.038","volume":"111","author":"MH Davidson","year":"2013","unstructured":"Davidson, M. H.  et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index \u226527 kg\/m2. Am. J. Cardiol. 111, 1131\u20131138 (2013).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo2013113_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","volume":"71","author":"S Hunt","year":"2008","unstructured":"Hunt, S.  et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71, 272\u2013276 (2008).","journal-title":"Neurology"},{"key":"BFnrendo2013113_CR35","first-page":"525","volume":"2","author":"SG Bryant","year":"1983","unstructured":"Bryant, S. G., Guernsey, B. G. & Ingrim, N. B. Review of bupropion. Clin. Pharm. 2, 525\u2013537 (1983).","journal-title":"Clin. Pharm."},{"issue":"Suppl. 4","key":"BFnrendo2013113_CR36","first-page":"66","volume":"59","author":"MG Goldstein","year":"1998","unstructured":"Goldstein, M. G. Bupropion sustained release and smoking cessation. J. Clin. Psychiatry 59 (Suppl. 4), 66\u201372 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"BFnrendo2013113_CR37","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1517\/14656560902775750","volume":"10","author":"RA Plodkowski","year":"2009","unstructured":"Plodkowski, R. A.  et al. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin. Pharmacother. 10, 1069\u20131081 (2009).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrendo2013113_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway, F. L.  et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 17, 30\u201339 (2009).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2013113_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nn1455","volume":"8","author":"RD Cone","year":"2005","unstructured":"Cone, R. D. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 8, 571\u2013578 (2005).","journal-title":"Nat. Neurosci."},{"key":"BFnrendo2013113_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.mehy.2010.09.002","volume":"76","author":"AS Reece","year":"2011","unstructured":"Reece, A. S. Hypothalamic opioid\u2013melanocortin appetitive balance and addictive craving. Med. Hypotheses 76, 132\u2013137 (2011).","journal-title":"Med. Hypotheses"},{"key":"BFnrendo2013113_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","volume":"17","author":"PP Lobmaier","year":"2011","unstructured":"Lobmaier, P. P., Kunoe, N., Gossop, M. & Waal, H. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci. Ther. 17, 629\u2013636 (2011).","journal-title":"CNS Neurosci. Ther."},{"key":"BFnrendo2013113_CR42","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1210\/jc.2009-1350","volume":"94","author":"FL Greenway","year":"2009","unstructured":"Greenway, F. L.  et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J. Clin. Endocrinol. Metab. 94, 4898\u20134906 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2013113_CR43","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1517\/14656566.2011.591382","volume":"12","author":"SK Billes","year":"2011","unstructured":"Billes, S. K. & Greenway, F. L. Combination therapy with naltrexone and bupropion for obesity. Expert Opin. Pharmacother. 12, 1813\u20131826 (2011).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrendo2013113_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/0361-9230(85)90115-7","volume":"14","author":"CA Maggio","year":"1985","unstructured":"Maggio, C. A.  et al. Naltrexone and human eating behaviour: a dose-ranging inpatient trial in moderately obese men. Brain Res. Bull. 14, 657\u2013661 (1985).","journal-title":"Brain Res. Bull."},{"key":"BFnrendo2013113_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway, F. L.  et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376, 595\u2013605 (2010).","journal-title":"Lancet"},{"key":"BFnrendo2013113_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden, T. A.  et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behaviour modification: the COR-BMOD trial. Obesity (Silver Spring) 19, 110\u2013120 (2011).","journal-title":"Obesity (Silver Spring)"},{"key":"BFnrendo2013113_CR47","unstructured":"Orexigen Therapeutics Inc. FDA Briefing Document NDA 200063 \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrendo2013113_CR48","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jclinepi.2004.04.004","volume":"57","author":"RD Crosby","year":"2004","unstructured":"Crosby, R. D., Kolotkin, R. L. & Williams, G. R. An integrated method to determine meaningful changes in health-related quality of life. J. Clin. Epidemiol. 57, 1153\u20131160 (2004).","journal-title":"J. Clin. Epidemiol."},{"key":"BFnrendo2013113_CR49","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.ijo.0803631","volume":"31","author":"R Padwal","year":"2007","unstructured":"Padwal, R., Kezouh, A., Levine, M. & Etminan, M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int. J. Obes. (Lond.) 31, 1567\u20131570 (2007).","journal-title":"Int. J. Obes. (Lond.)"},{"key":"BFnrendo2013113_CR50","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.psc.2011.08.013","volume":"34","author":"GA Bray","year":"2011","unstructured":"Bray, G. A. & Ryan, D. H. Drug treatment of obesity. Psychiatr. Clin. North Am. 34, 871\u2013880 (2011).","journal-title":"Psychiatr. Clin. North Am."},{"key":"BFnrendo2013113_CR51","doi-asserted-by":"publisher","first-page":"E1059","DOI":"10.1503\/cmaj.110387","volume":"183","author":"RS Padwal","year":"2011","unstructured":"Padwal, R. S., Pajewski, N. M., Allison, D. B. & Sharma, A. M. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 183, E1059\u2013E1066 (2011).","journal-title":"CMAJ"},{"key":"BFnrendo2013113_CR52","unstructured":"Committee on National Statistics & Behavioural and Social Sciences and Education. The Prevention and Treatment of Missing Data in Clinical Trials (National Academies Press, 2010)."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.113","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2013.113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:40:40Z","timestamp":1684467640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2013.113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFnrendo2013113"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2013.113","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]}}}